Ⅰ期非小细胞肺癌发生淋巴结微转移的检测与预后研究进展  

Research progress of lymph node micrometastasis detection and prognosis in stage Ⅰ non-small cell lung cancer

作　　者：赵炜杰 赵光强[1] 叶联华[1] ZHAO Wei-jie;ZHAO Guang-qiang;YE Lian-hua(Department of Thoracic Surgery,the Third Affiliated Hospital of Kunming Medical University/Tumor Hospital of Yunnan Province,Kunming 650118,Yunnan,China)

机构地区：[1]昆明医科大学第三附属医院/云南省肿瘤医院胸外科一病区

出　　处：《医学研究生学报》2019年第10期1094-1098,共5页Journal of Medical Postgraduates

基　　金：国家自然科学基金(81860325)

摘　　要：手术是治疗Ⅰ期非小细胞肺癌(NSCLC)的首选方式,影响NSCLC预后的主要原因是肿瘤的转移和复发。近年来研究发现淋巴结微转移是Ⅰ期NSCLC患者死亡的主要原因。微转移逐渐成为现代精准医学的研究热点,尽早发现微转移对肺癌的诊断,早期干预及精准判断预后具有重要意义。文章主要从淋巴结微转移的概念、临床检测方法和检测标记物、以及对预后和辅助治疗等方面进行综述。Surgery is preferred for treating stageⅠnon-small cell lung cancer(NSCLC).The main factors that affecting its prognosis are tumor metastasis and recurrence.In recent years,studies have revealed that the main cause of death in patients with stageⅠNSCLC is micrometastasis of lymph nodes.Micrometastasis has become a hot topic in modern precision medicine.Detection of micrometastasis as early as possible,early intervention and accurate assessment on prognosis of lung cancer have a great impact.The concept,methods and markers for clinical detection,as well as prognosis and adjuvant therapy of lymph node micrometastasis are reviewed in this article.

关 键 词：肺肿瘤 淋巴结 微转移 检测 预后 

分 类 号：R734.2[医药卫生—肿瘤]